1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Becton, Dickinson and Company

Becton, Dickinson and Company

BDX
Becton, Dickinson and CompanyUS flagNew York Stock Exchange
184.74
USD
-2.88
- -
50.90BMarket Cap
Becton, Dickinson and Company
BDX
(New York Stock Exchange)

Recent

price

184.74

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
30.4
34.29
37.52
41.27
43.69
50.77
58.69
55.23
61.86
64.05
57.62
66.13
66.21
67.67
69.64
75.93
74.34
Revenue per Share
5.62
5.75
5.69
6.63
6.13
3.43
4.59
4.7
0.62
4
2.75
6.92
5.93
4.97
5.88
5.83
3.36
Basic EPS, GAAP
7.04
7.35
8.58
8.81
9.02
8.54
12.03
11.65
11.09
12.34
12.69
16.07
9.24
10.44
13.1
11.93
11.64
Free Cash Flow per Basic Share
1.48
1.63
1.79
1.98
2.18
2.39
2.64
3.09
3.59
3.65
3.68
3.62
3.8
3.89
3.8
4.16
4.18
Dividend per Share
23.65
22.48
21
25.99
26.33
34.01
35.79
56.8
78.26
77.95
81.94
83.22
89.22
88.84
89.55
88.96
89.64
Book Value per Share
16.87
12.67
9.65
14.06
14.78
-36.83
-28.44
-2.24
-71.02
-63.87
-47.14
-45.68
-41.11
-33.31
-39.75
-37.23
-35.05
Tangible Book Value per Share
234
221
205
195
193
203
213
219
258
270
279
289
285
286
290
288
280
Basic Weighted Avg Shares
7,124
7,584
7,708
8,054
8,446
10,282
12,483
12,093
15,983
17,290
16,074
19,131
18,870
19,372
20,178
21,840
20,840
Sales/Revenue/Turnover
22.21
21.95
20.21
15.58
19.01
14.59
17.29
15.51
14.07
12.96
7.53
12.7
13.12
12.51
14.15
13.67
13.75
Operating Margin (%)
491
494
511
546
562
891
1,114
1,088
1,978
2,253
2,115
2,230
2,229
2,288
2,286
2,462
2,326
Depreciation Expense
1,318
1,271
1,170
1,293
1,185
695
976
1,100
311
1,233
874
2,092
1,779
1,484
1,705
1,678
941
Net Income, GAAP
28.84
25.77
24.66
20.26
22.14
5.95
9.03
- -
73.49
- -
14.98
5.2
8.3
7.94
14.96
10.79
13.77
Effective Tax Rate (%)
18.49
16.76
15.18
16.05
14.03
6.76
7.82
9.1
1.95
7.13
5.44
10.94
9.43
7.66
8.45
7.68
4.52
Profit Margin (%)
2,834
2,845
3,344
3,743
3,896
1,278
1,967
15,291
195
1,009
3,133
2,212
330
2,035
1,512
942
-1,265
Working Capital
1,495
2,485
3,761
3,763
3,768
11,370
10,550
18,667
18,894
18,081
17,224
17,110
13,886
14,738
17,940
17,621
13,511
LT Debt
5,435
4,828
4,136
5,042
5,053
7,165
7,634
12,948
20,994
21,082
23,765
23,677
25,282
25,797
25,889
25,390
24,416
Total Equity
15.86
16.84
14.84
11.54
13.83
9.71
9.95
- -
1.59
- -
2.5
5.53
5.47
5.36
5.53
5.86
5.74
Return on Invested Capital (%)
19.12
18.16
16.05
16.21
14.31
7.2
6.79
- -
1.34
- -
3.22
6.11
5.19
4.58
4.91
4.91
3.37
Return on Capital (%)
24.91
24.77
26.1
28.18
23.48
11.38
13.19
10.01
0.94
5.14
3.42
8.44
6.9
5.58
6.6
6.54
3.77
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
2,623
2,573
3,297
LT Borrowings
16,916
14,706
13,511
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
285
276
272
Market Capitalization
43,443
43,323
41,220

Working Capital

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
9,189
8,012
8,139
Cash, Cash Equivalents & STI
751
816
709
Accounts Receivable, Net
2,508
2,205
2,364
Inventories
4,085
3,357
3,316
Total Current Liabilities
8,761
8,507
9,404
Payables & Accruals
6,138
5,934
6,107
ST Debt
2,623
2,573
3,297
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.83%
1.38%
-1.93%
Free Cash Flow
10.14%
3.78%
-9.64%
Net Income, GAAP
36.99%
24.23%
-1.58%
Sales/Revenue/Turnover
8.43%
6.54%
8.24%
Total Cash Common Dividend
9.65%
5.43%
8.73%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,706
5,045
4,990
5,437
20,178
2025
5,168
4,480
4,726
5,891
21,840
2026
5,252
4,714
4,983
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.97
1.85
1.68
1.38
5.88
2025
1.05
1.07
2
- -
5.83
2026
1.34
-1.11
1.37
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.95
0.95
0.95
0.95
3.8
2025
1.04
1.04
1.04
- -
4.16
2026
1.05
1.03
1.04
- -
- -
Similar Companies
Elegance Optical International Holdings Limited (0907.HK)
Asahi Intecc Co., Ltd. (7747.T)
DENTSPLY SIRONA Inc. (DY2.F)
Signature Eyewear, Inc. (SEYE)
Paradigm Medical Industries, Inc. (PDMI)
Reflect Scientific, Inc. (RSCF)
Business
Becton, Dickinson and Company (BDX) manufactures and distributes medical devices, instrument systems, and reagents worldwide. The company develops, produces, and sells a broad portfolio of products including syringes, catheters, infusion therapy devices, and diagnostic systems; safety-engineered sharps and vascular access products; BD Alaris infusion pumps and Pyxis medication management solutions; BD FACSAria flow cytometers and Rhapsody single-cell analysis platforms; and laboratory automation systems such as BD Kiestra and BD Synapsys informatics. BD operates in three main segments—BD Medical, BD Life Sciences, and BD Interventional—serving healthcare facilities, laboratories, pharmaceutical companies, and research institutions across North America, Europe, Asia-Pacific, and emerging markets. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD maintains a global presence with manufacturing facilities in more than 50 countries. In recent developments, BD completed the spin-off of its Biosciences solution business into a standalone entity in early 2025, enabling focused growth in high-margin diagnostics and cell analysis; the company also expanded its partnership with GE HealthCare for integrated medication management technologies and launched new Alaris iPC infusion pump features to enhance cybersecurity and interoperability.

Company News

Company News APIChatGPT

  • gurufocus.com

    BDX DCF Analysis: Intrinsic Value $157 vs Price $187

  • 247wallst.com

    Two Recessions Couldn't Stop These 4 Healthcare Stocks From Raising Dividends

  • 247wallst.com

    Jim Cramer Calls This Mining Stock an Inflation Hedge “Just as Good as Crypto”

  • prnewswire.com

    BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation

  • prnewswire.com

    BD to Present at Wells Fargo 21st Annual Healthcare Conference

  • gurufocus.com

    BDX DCF Analysis: Intrinsic Value $157 vs Price $190

  • zacks.com

    BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study

  • prnewswire.com

    BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire

  • zacks.com

    Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH

  • seekingalpha.com

    Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing

  • gurufocus.com

    BDX DCF Analysis: Intrinsic Value $141 vs Price $181

  • prnewswire.com

    BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial

  • gurufocus.com

    First Eagle Investment Buys Becton Dickinson & Co (BDX) -- Shares Look 6% Undervalued on GF Value

  • 247wallst.com

    We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.

  • gurufocus.com

    Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance Amid Tariff Pressures

  • marketbeat.com

    Becton, Dickinson and Company Q3 Earnings Call Highlights

  • zacks.com

    BD Stock Up in Pre-Market Post Q3 Earnings & Revenue Beat, Margins Down

  • seekingalpha.com

    Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript

  • benzinga.com

    Becton Dickinson Signals Strong Growth Momentum By Raising Profit Outlook

  • zacks.com

    Becton Dickinson (BDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates